Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Lasmiditan - Eli Lilly and Company

Next Previous
Drug Profile

Lasmiditan - Eli Lilly and Company

Alternative Names: COL-144; LY-573144; Rayvow; REYVOW

Latest Information Update: 24 Mar 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Eli Lilly and Company; Lundbeck A/S
  • Developer Eli Lilly and Company; Ildong Pharmaceutical
  • Class Antimigraines; Benzamides; Fluorinated hydrocarbons; Piperidines; Pyridines; Small molecules
  • Mechanism of Action Serotonin 1F receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Migraine

Most Recent Events

  • 10 Mar 2026 Eli Lilly and Company terminates a the phase III PIONEER-PEDS2 trial for Migraine (In adolescents, In children) in USA, Czech Republic and Japan (PO) due to strategic business decision (NCT04396574)
  • 10 Mar 2026 Eli Lilly and Company terminates the phase III PIONEER-PEDS1 trial for Migraine (In children, In adolescents) in USA and Japan (PO,Tablet) (NCT04396236) (EudraCT2019-004378-24)
  • 02 Nov 2023 Launched for Migraine in Hungary (PO)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top